EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

Abstract

Pediatric growth hormone deficiency (pGHD) is defined as growth failure associated with inadequate growth hormone (GH) production. Daily injections of recombinant human GH (dGH) [somatropin] is the current standard of care, which has been shown to be safe and effective, however with suboptimal adherence, leading to reduced effectiveness. Somatrogon, a once-weekly injectable long-acting human GH, has demonstrated clinical non-inferiority and significantly lower life interference vs. somatropin. This work aimed to evaluate cost-effectiveness and cost-utility of somatrogon vs dGHs across 5 countries (United States, Canada, Spain, Sweden, Ireland)